menu
    • menu
    [{"orgOrder":0,"company":"DepYmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DPM-1001","moa":"PTP1B","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"DepYmed","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DepYmed \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"DepYmed \/ Inapplicable"},{"orgOrder":0,"company":"DepYmed","sponsor":"Monash Biomedicine Discovery Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"PTP1B","graph1":"Oncology","graph2":"Preclinical","graph3":"DepYmed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"DepYmed \/ Monash Biomedicine Discovery Institute","highestDevelopmentStatusID":"4","companyTruncated":"DepYmed \/ Monash Biomedicine Discovery Institute"},{"orgOrder":0,"company":"DepYmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DPM-1003","moa":"PTP1B","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"DepYmed","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"DepYmed \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"DepYmed \/ Inapplicable"},{"orgOrder":0,"company":"DepYmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"DPM-1003","moa":"PTP1B","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"DepYmed","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"DepYmed \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"DepYmed \/ Inapplicable"},{"orgOrder":0,"company":"DepYmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DPM-1003","moa":"PTP1B","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"DepYmed","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"DepYmed \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"DepYmed \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by DepYmed

    Menu

    DepYmed

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            DepYmed

                            U.S.A arrow
                            Arvo
                            Not Confirmed

                            DepYmed

                            U.S.A arrow
                            Arvo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DPM-1003

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            DepYmed Receives FDA Clearance to Start Phase 1 Trial for DPM-1003 in Rett Syndrome

                            Details : DPM-1003 orally bioavailable drug candidates that act by inhibiting PTP1B, which is being evaluated for the treatment of patients suffering from Rett Syndrome.

                            Product Name : DPM-1003

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 19, 2024

                            Lead Product(s) : DPM-1003

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            DepYmed

                            U.S.A arrow
                            Arvo
                            Not Confirmed

                            DepYmed

                            U.S.A arrow
                            Arvo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DPM-1003

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            DepYmed Receives European Medicines Agency Orphan Drug Designation for Its Lead Clinical Candidate for the Tre...

                            Details : DepYmed is the first company to develop a new class of orally bioavailable drug candidates that act by inhibiting PTP1B, one of the most important PTP drug targets.

                            Product Name : DPM-1003

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 16, 2022

                            Lead Product(s) : DPM-1003

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            DepYmed

                            U.S.A arrow
                            Arvo
                            Not Confirmed

                            DepYmed

                            U.S.A arrow
                            Arvo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Monash Biomedicine Discovery Institute

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            DepYmed and Monash Biomedicine Discovery Institute to Study the Role of a New Generation of PTP1B Inhibitors A...

                            Details : DepYmed is developing a new class of drug candidates that act by inhibiting PTP1B. The research sponsored under the new agreement aims to confirm that its drug candidates also target this intracellular checkpoint mechanism and inhibit tumor growth in pre...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 03, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Monash Biomedicine Discovery Institute

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            DepYmed

                            U.S.A arrow
                            Arvo
                            Not Confirmed

                            DepYmed

                            U.S.A arrow
                            Arvo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DPM-1001

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            DepYmed Receives FDA Orphan Drug Designation for Clinical Candidate DPM-1001 for the Treatment of Wilson Disea...

                            Details : DPM-1001, a small molecule PTP1B inhibitor that also has high specificity and high affinity for binding copper and is therefore being studied in Wilson Disease.

                            Product Name : DPM-1001

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 23, 2022

                            Lead Product(s) : DPM-1001

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            DepYmed

                            U.S.A arrow
                            Arvo
                            Not Confirmed

                            DepYmed

                            U.S.A arrow
                            Arvo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DPM-1003

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            DepYmed Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Its Lead Clinical Candidate for t...

                            Details : U.S. FDA has granted Rare Pediatric Disease and Orphan Drug designations for its lead clinical candidate, a small molecule PTP1B inhibitor for the treatment of patients with Rett Syndrome.

                            Product Name : DPM-1003

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 05, 2022

                            Lead Product(s) : DPM-1003

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth